Demyelinating polyneuropathy in eosinophilia–myalgia syndrome

Eosinophilia–myalgia syndrome (EMS) is a newly recognized disorder, characterized by myalgia, weakness, scleroderma‐like changes, and eosinophilia. EMS is associated with lots of L‐tryptophan allegedly contaminated with byproducts of the manufacturing process. We describe 3 patients with EMS who presented with a severe demyelinating sensorimotor polyneuropathy. Electrodiagnostic studies revealed multifocal conduction block, slowing and temporal dispersion of motor responses, and prolonged or absent F‐responses. Despite plasmapheresis; corticosteroids; and, in 1 patient, cyclophosphamide, 2 patients died and the remaining patient experienced minimal recovery. Pathology revealed patchy perivascular infiltrates and fibrosis in the connective tissue of muscle and nerve. Autopsy of the central nervous system in 2 patients did not reveal changes unique to EMS. In addition to other organ involvement, EMS may manifest as a potentially fatal polyneuropathy, which initially appears to have prominent demyelinating features.

[1]  C. Lombard,et al.  L-tryptophan and the eosinophilia-myalgia syndrome: pathologic findings in eight patients. , 1991, Human pathology.

[2]  M. Dalakas,et al.  L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. , 1990, The Journal of clinical investigation.

[3]  K. Sakimoto.  The cause of the eosinophilia-myalgia syndrome associated with tryptophan use. , 1990, The New England journal of medicine.

[4]  E. Kilbourne,et al.  Eosinophilia-Myalgia Syndrome: Results of National Surveillance , 1990 .

[5]  G. Parry,et al.  Peripheral neuropathy associated with eosinophilia‐myalgia syndrome , 1990, Annals of neurology.

[6]  L. Roberts.  L-tryptophan puzzle takes new twist. , 1990, Science.

[7]  M. Osterholm,et al.  An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. , 1990, The New England journal of medicine.

[8]  L. Kaufman,et al.  L‐Tryptophan‐Associated Eosinophilic Perimyositis, Neuritis, and Fasciitis: A Clinicopathologic and Laboratory Study of 25 Patients , 1990, Medicine.

[9]  P. Dyck,et al.  Peripheral neuropathy in the eosinophilia‐myalgia syndrome associated with l‐tryptophan ingestion , 1990, Neurology.

[10]  G. Gleich,et al.  Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. , 1990, The New England journal of medicine.

[11]  E. Sternberg,et al.  Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. , 1990, The New England journal of medicine.

[12]  D. Clauw,et al.  Tryptophan-associated eosinophilic connective-tissue disease. A new clinical entity? , 1990, JAMA.

[13]  S. Furukawa,et al.  Neurotoxicity of human eosinophils towards peripheral nerves , 1989, Journal of the Neurological Sciences.

[14]  C. Giannini,et al.  Polyneuropathy in hypereosinophilic syndrome , 1988, Neurology.

[15]  J. Albers,et al.  Acute arsenic intoxication presenting as guillainbarréa‐like syndrome , 1987, Muscle & nerve.

[16]  A. Borgeat,et al.  Peripheral neuropathy associated with high‐dose ara‐C therapy , 1986, Cancer.

[17]  J. Jacobs,et al.  The pathology of amiodarone neurotoxicity. II. Peripheral neuropathy in man. , 1985, Brain : a journal of neurology.

[18]  J. Jacobs,et al.  The pathology of amiodarone neurotoxicity. I. Experimental studies with reference to changes in other tissues. , 1985, Brain : a journal of neurology.

[19]  F Buchthal,et al.  Peripheral neuropathy in hypereosinophilic syndrome , 1985, Neurology.

[20]  J. Pollard,et al.  Glue sniffing neuropathy. , 1985, Australian and New Zealand journal of medicine.

[21]  A. Watt,et al.  Peripheral neuropathy during longterm high-dose amiodarone therapy. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[22]  J. Horowitz,et al.  Perhexilene neuropathy: a report of two cases. , 1984, Australian and New Zealand journal of medicine.

[23]  E. Kilbourne,et al.  Clinical epidemiology of toxic-oil syndrome. Manifestations of a New Illness. , 1983, The New England journal of medicine.

[24]  L. Forno,et al.  Neuropathy in the hypereosinophilic syndrome , 1983, Muscle & nerve.

[25]  R. Baloh,et al.  Myoclonus and ocular oscillations induced by L‐tryptophan , 1982, Annals of neurology.

[26]  D. Durack,et al.  Purification of human eosinophil-derived neurotoxin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Abdul-Kader,et al.  Clinical and electrophysiological studies of diphtheritic neuritis in Jordan , 1979, Journal of the Neurological Sciences.

[28]  S. Wolff,et al.  THE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature , 1975, Medicine.

[29]  S. Wolff,et al.  The hypereosinophilic syndrome , 1975 .

[30]  P C O'Brien,et al.  Segmental demyelination secondary to axonal degeneration in uremic neuropathy. , 1971, Mayo Clinic proceedings.

[31]  C. Pare.  POTENTIATION OF MONOAMINE-OXIDASE INHIBITORS BY TRYPTOPHAN. , 1963, Lancet.

[32]  D. Prockop,et al.  Central-nervous-system effects of ingestin of L-tryptophan by normal subjects. , 1962, The New England journal of medicine.